Sign up Australia
Proactive Investors - Run By Investors For Investors

PressureBioSciences upbeat after fund-raising tops expectations

The company has increased the capacity of the offering to a maximum of US$6.25 million.
PressureBioSciences upbeat after fund-raising tops expectations
Having cleared its variable convertible debt, the company can invest the funds in ramping up sales promotion

Pressure BioSciences (OTCMKTS:PBIO), the pressure cycling technology company, has exceeded its US$5mln private investment in public equity (PIPE) goal.

The company announced the passing of the milestone following the receipt of $255,000 in gross proceeds from the fifth closing of its $5 million private placement. This closing increased the total amount raised in the offering to $5,010,000, which is actually more than the offering was supposed to raise, so the company increased the capacity of the PIPE to a maximum of US$6.25mln.

"The vast majority of funds raised to date have been used to eliminate 100% of the company's variable rate (floorless) convertible debt. With our significantly improved balance sheet now in hand, all funds received from the over-subscription amount will be used to support operating activities,” said Richard Schumacher, president and chief executive officer of Pressure BioSciences.

“With ramping sales, new and further improved product offerings, the planned expansion of our sales and marketing capabilities, and the expected announcement of a world-class, formidable, multi-national co-marketing partner, we believe we will achieve operational and financial growth levels in 2016 that will surpass any previous year, including our record shattering 2015 performance," Schumacher added.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

September 28 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
myLotus testing kit
October 31 2018
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 06 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use